How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer’s disease? And what on Earth is an “oversubscribed Series A round”?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation with Dr. Peter Bach of Memorial Sloan Kettering Cancer Center about just how the government should pay for those pricey-but-effective new CAR-T therapies. Then we break down some of the jargon startups employ when they raise money and explain why some of it doesn’t exactly mean what you might think. Also STAT’s Sharon Begley joins us to talk about why the drug industry’s Alzheimer’s pipeline offers so little hope to patients already showing symptoms of the disease, and we embark on a lightning round touching on Gilead Sciences’ changing of the guard, gene therapy’s commercial future, and why good news at the FDA can be bad news on Wall Street.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy